Shanghai study finds recovered COVID-19 patients have persistent immune protection
The latest Shanghai-based study has found that the majority of recovered COVID-19 patients have persistent immune protection and vaccination may trigger a durable immune response.
Kaspersky study finds support for human augmentation
Nearly two-thirds of people in leading Western European countries would consider augmenting the human body with technology to improve their lives, mostly to improve health, according to research commissioned by Kaspersky.
No antibody-dependent enhancement effect observed in China-developed COVID19 vaccines: experts
ADE has been observed in many viruses, especially the notorious dengue disease and feline infectious peritonitis, a progressive and fatal disease caused by the feline coronavirus that is closely related to novel coronavirus, which led to people's concerns, Gao told the Global Times.
China seeks to manage supply of horseshoe crab's indispensable blood in race to develop COVID-19 vaccines
Declining number of horseshoe crabs - the alien-looking marine creature with blue blood containing ancient immunity properties that are an essential to develop a COVID-19 vaccine - has scientist, pharmaceutical companies, NGOs and local governments worried.
Patient zero not always found among first cluster, so who and where is this person?
A senior World Health Organization (WHO) official highlighted at the organization's most recent press conference that patient zero is not necessarily found among the first cluster of coronavirus cases, suggesting that Wuhan, where the first COVID-19 outbreak was reported in China, may very well not be the source of the epidemic and bringing the hunt for patient zero back into spotlight.
China's ambassador to Bangladesh offers to take part in clinical trial of China-made COVID-19 vaccine
China's Embassy to Bangladesh confirmed with the Global Times that Ambassador Li Jiming has said that he would be willing to be the first volunteer for the upcoming phase III clinical trial of a vaccine candidate developed by Chinese company Sinovac Life Sciences Co., Ltd. in Bangladesh.
Chinese COVID-19 vaccine approved to enter Phase III clinical trial in Brazil
Beijing-based Sinovac Life Sciences Co announced on Monday that its COVID-19 vaccine collaboration with Brazilian immunobiologic producer Instituto Butantan has received approval from the Brazilian regulator for phase III clinical trials.
Chinese COVID-19 vaccine candidate the first to start phase 3 clinical trials worldwide
Chinese-developed COVID-19 vaccine candidate is the world's first to enter phase three human clinical trial which will begin in the United Arab Emirates (UAE) on Tuesday. It is also the first overseas clinical trial for a Chinese-grown vaccine, and is seen as an important step toward putting the vaccine into use and benefiting all humanity.
Cell journal publishes China's COVID-19 vaccine breakthrough
China has developed an inactivated SARS-CoV-2 vaccine candidate, BBIBP-CorV. Related research and development of the COVID-19 inactivated vaccine was published by "Cell" on Saturday, one of the world's most respected life science academic journals.
Hantavirus return is no cause for alarm
Diseases throughout history were contained after countries implemented prevention measures by developing medicine, disinfectants, and face masks.